Wikipedia -WSS

Wikipedia

author：fashion 2025-09-02 09:38:17 - browse：8518

Courtesy Guardant Health

An independent panel of advisers to the Food and Drug Administration recommended the agency approve Guardant Health’s blood-based colon cancer detection test. If the agency follows the recommendation, it will clear an early hurdle for the test’s broader adoption.

The expert panel spent hours listening to presentations from Guardant, the FDA, and members of the public before voting on the screening test, called Shield. The panel’s nine voting members then voted on whether the test was safe, effective, and whether its benefits outweigh its risks, with eight, six, and seven panelists endorsing those views, respectively.

FDA approval is a requirement for winning coverage from the Centers for Medicare and Medicaid Services, which could be the difference between Guardant’s test becoming widespread — or irrelevant. In 2021, CMS denied coverage for Epi proColon, a different blood-based colon cancer test approved by the FDA. Soon after, the test’s maker, Epigenomics, announced that it would stop actively marketing the test, and last year the company announced a restructuring that included layoffs.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Transgender women dream of pregnancy via uterus transplants

WSS

CommonSpirit Health keeps growing, even as it loses money

Where does female orgasm come from? Scientists think they know

New requirements coming in 2024 for Americans traveling to Europe

Weekend shootings leave at least 6 dead, 20 others wounded in Chicago

Sophia Smith scores twice for US in in 3

Clinic falsely told dozens they had Alzheimer's, suits say

explore

Wikipedia

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Jerome Adams on the need for new antivirals for Covid

PrEP can help anyone prevent HIV. Why do so few people take it?

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

Psychedelics group wrestles with new pharma identity

Where does female orgasm come from? Scientists think they know

Medical leaders decry Supreme Court decision on affirmative action

FAMU bans football players from facility after release of rap video shot in team's locker room

New air purifier tech could be key to improving indoor air quality

Biotech stock slump in 2023: awaiting the turnaround

entertainment

Readout LOUD podcast: possible new ALS drug, artificial wombs

How Vertex's cystic fibrosis drug is changing patients' lives

'The Earth is screaming at us': Gov. Inslee calls for climate action amid record heat

CDC advisers recommend seasonal use of Pfizer RSV shot

Drug for rare kidney disease narrowly misses mark in clinical trial

Intarcia’s device

focus

focus

hotspot

focus